Dr. Salma Jabbour’s NCI Research Specialist (Clinician Scientist) Award (R50)

Salma Jabbour 博士荣获 NCI 研究专家（临床科学家）奖 (R50)

• 批准号: 10563885
• 负责人: Salma Jabbour
• 金额: $ 19.62万
• 依托单位: RUTGERS BIOMEDICAL AND HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10563885
• 关键词: American College of Radiology Imaging Network; Award; Cancer Institute of New Jersey; Cancer Therapy Evaluation Program; Caring; Clinical; Clinical Trials; Clinical Trials Network; Collaborations; Combined Modality Therapy; Complex; Development; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Funding; Grant; Human; Institution; Interest Group; Leadership; Malignant Neoplasms; Mentors; Mentorship; Oncology; Patient Care; Patients; Physicians; Play; Protocols documentation; Radiation; Research; Research Personnel; Role; Scientist; Seasons; Services; Specialist; Time; Work; cancer care; cancer clinical trial; career; design; gastrointestinal; innovation; novel; programs

ABSTRACT Oncology clinical trials are increasingly complex in their design, management, and oversight, and clinical trials continue as the cornerstone to transform cancer care for patients. These multifaceted trials require significant partnership from the institution and investigators to provide support and effort as well as multifaceted teams to conduct and execute these trials seamlessly and effectively. Furthermore, the dissemination of clinical trial findings in a timely and efficient manner requires the continued support from the clinical trials teams, biostatisticians, and co-investigators in terms of time and effort. Dr. Jabbour is a seasoned research specialist, physician scientist, and clinician scientist having a proven track record of diligence and innovation as well as purpose to design, carry out, and complete clinical trials. Her long-standing commitment to clinical trials is paramount as she is a leader at the Rutgers Cancer Institute of New Jersey in mentoring and supporting other clinical trialists, having overseen the Human Research Oversight Committee (HROC/DSMB) and currently overseeing the Scientific Review Board, and she plays integral role in the oversight of clinical trials through a variety of committees both at Rutgers Cancer Institute and nationally. At the national level, Dr. Jabbour is the contact PI for the Rutgers Cancer Institute ETCTN/CTEP grant funding, is a long-standing Co-Chair for the NCI Radiation Research Program Gastrointestinal Interest Group, and is actively involved in a variety of NCI Cooperative Group Committees and Protocols including the ECOG-ACRIN and NRG Oncology Cooperative Groups. Dr. Jabbour is a continued leader and pioneer as a clinician scientist and actively studies the use of novel agents in combination with radiation in ground-breaking clinical trials. Dr. Jabbour will continue her exemplary efforts and work under the auspices of this R50 Mechanism and will continue to revolutionize the care for oncology patients through her state-of-the-art concepts and collaborations through the NCI national cooperative groups.

抽象的 肿瘤学临床试验的设计，管理和监督以及临床试验越来越复杂 继续作为改变患者癌症护理的基石。这些多方面试验需要重大 机构和调查人员的合作伙伴关系，以提供支持和努力以及多方面的团队 无缝和有效地进行和执行这些试验。此外，临床试验的传播 调查结果及时有效，需要临床试验团队的持续支持， 在时间和精力方面，生物统计学家和共同投资者。 Jabbour博士是一位经验丰富的研究专家， 医师科学家和临床医生科学家具有良好的勤奋和创新记录以及 设计，执行和完成临床试验的目的。她对临床试验的长期承诺是 派拉蒙（Paramount）是她是新泽西州罗特斯癌症研究所的领导者，以指导和支持其他 临床试验员，负责监督人类研究监督委员会（HROC/DSMB）和目前 监督科学审查委员会，她在临床试验中扮演不可或缺的角色 罗格斯癌症研究所和全国范围内的各种委员会。在国家一级，贾布尔博士是 与Rutgers Cancer Institute ETCTN/CTEP拨款资金联系的PI是NCI的长期联席主席 辐射研究计划胃肠道兴趣组，并积极参与多种NCI 合作小组委员会和协议，包括ECOG-ACRIN和NRG肿瘤合作社 组。 Jabbour博士是临床医生的持续领导和先驱，并积极研究 在开创性临床试验中，新型药物与辐射结合使用。贾布尔博士将继续她 在这种R50机制的主持下的典范努力和工作，并将继续革新 通过NCI国家的最新概念和合作来照顾肿瘤学患者 合作团体。